Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: Data from MonaldiCare registry

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 20, 2015, Pages 3961-3967

  Russo, V ^a   Bianchi, V ^b   Cavallaro, C ^b   Vecchione, F ^b   De Vivo, S ^b   Santangelo, L ^a   Sarubbi, B ^a   Calabro P ^a   Nigro, G ^a   D'Onofrio, A ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b MONALDI HOSPITAL   (Italy)

Author keywords

Bleeding; Dabigatran; Efficacy; Novel oral Anticoagulants; Real life; Safety; Stroke

Indexed keywords

DABIGATRAN; ANTITHROMBIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLADDER BLEEDING; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVERSION; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; FOOD INTAKE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDY; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHEMICALLY INDUCED; HEALTH SURVEY; HEMORRHAGE; ITALY; MIDDLE AGED; PREVALENCE; PROCEDURES; REGISTER; RISK FACTOR; STROKE; TREATMENT OUTCOME;

AGED; ANTITHROMBINS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; ITALY; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84966400945     PISSN: 11283602     EISSN: 22840729     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. STEWART S, HART CL, HOLE DJ, MCMURRAY JJ. Population prevalence, prevalence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-521.
2. WATSON T, SHANTSILA E, LIP GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373: 155-166.
3. AGUILAR MI, HART R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; (3): CD001927.
4. LIP GY, NIEUWLAAT R, PISTERS R, LANE DA, CRIJNS HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
5. GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
6. LANDEFELD CS, BEYTH RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328.
7. PROIETTI R, PORTO I, LEVI M, LEO A, RUSSO V, KALFON E, BIONDI-ZOCCAI G, ROUX JF, BIRNIE DH, ESSEBAG V. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. Eur Rev Med Pharmacol Sci 2015; 19: 1461-1479.
8. STANGIER J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
9. CONNOLLY SJ, EZEKOWITZ MD, YUSUF F, EIKELBOOM J, OLDGREN J, PAREKH A, POGUE J, REILLY PA, THEMELES E, VARRONE J, WANG S, ALINGS M, XAVIER D, ZHU J, DIAZ R,LEWIS BS, DARIUS H, DIENER HC, JOYNER CD, WALLENTIN L; RE-LY STEERING COMMITTEE AND INVESTIGATORS. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. GRAHAM DJ, REICHMAN ME, WERNECKE M, ZHANG R, SOUTHWORTH MR, LEVENSON M, SHEU TC, MOTT K, GOULDING MR, HOUSTOUN M, MACURDY TE, WORRALL C, KELMAN JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
11. PROIETTI R, JOZA J, ARENSI A, LEVI M, RUSSO V, TZIKAS A, DANNA P, SAGONE A, VIECCA M, ESSEBAG V. Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. Med Devices (Auckl) 2015; 8: 103-114.
12. DANNA P, PROIETTI R, SAGONE A, ARENSI A, VIECCA M, RAGO A, RUSSO V. Does left atrial appendage closure with a cardiac plug system reduce the stroke risk in nonvalvular atrial fibrillation patients? A single-center case series. Pacing Clin Electrophysiol 2013; 36: 347-353.
13. OLDGREN J, EZEKOWITZ MD, ALINGS M, DIENER HC, REILLY PA, YUSUF S, WALLENTIN L, CONNOLLY S. Dabigatran versus warfarin and inpact od CHAD2-Vasc score on outocome in atrial fibrillation patients: a RE-LY subgroups analysis. J Am Coll Cardiol 2011; 57: E7-E7.
14. EIKELBOOM JW, CONNOLLY SJ, HART RG, WALLENTIN L, REILLY P, OLDGREN J, YANG S, YUSUF S. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol 2013; 62: 900-908.
15. RUSSO V, AMMENDOLA E, DE CRESCENZO I, DOCIMO L, SANTANGELO L, CALABRÒ R. Severe obesity and Pwave dispersion: the effect of surgically induced weight loss. Obes Surg. 2008; 18: 90-96.
16. NIGRO G, RUSSO V, POLITANO L, DELLA CIOPPA N, RAGO A, ARENA G, PAPA AA, PAOLI LD, DE CHIARA A, RUSSO MG, GOLINO P, CALABRÒ R. Does Bachmann's bundle pacing prevent atrial fibrillation in myotonic dystrophy type 1 patients? A 12 months follow-up study. Europace 2010; 12: 1219-1223.
17. RUSSO V, RAGO A, PALLADINO A, PAPA AA, DI MEO F, DELLA CIOPPA N, GOLINO P, RUSSO MG, CALABRÒ R, POLITANO L, NIGRO G. P-wave duration and dispersion in patients with emery-dreifuss muscular dystrophy. J Investig Med 2011; 59: 1151-1154.
18. NIGRO G, RUSSO V, RAGO A, ANTONIO PAPA A, PALLADINO A, POLITANO L. Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study. Acta Myol 2012; 31: 139-143.
19. RUSSO V, RAGO A, POLITANO L, DELLA CIOPPA N, RUSSO MG, GOLINO P, CALABRÒ R, NIGRO G. The effect of atrial preference pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: a prospective, randomized, singlebind cross-over study. Europace 2012; 14: 486-489.
20. RUSSO V, NIGRO G, RAGO A, ANTONIO PAPA A, PROIETTI R, DELLA CIOPPA N, CRISTIANO A, PALLADINO A, CALABRÒ R, POLITANO L. Atrial fibrillation burden in Myotonic Dystrophy type 1 patients implanted with dual chamber pacemaker: the efficacy of the overdrive atrial algorithm at 2 year follow-up. Acta Myol 2013; 32: 142-147.
21. RUSSO V, RAGO A, PAPA AA, POLITANO L, GOLINO P, RUSSO MG, CALABRÒ R, NIGRO G. Does a high percentage of right ventricular pacing influence the incidence of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients? Kardiol Pol 2013; 71: 1147-1453.
22. RUSSO V, NIGRO G, DI MEO F, PAPA AA, CIOPPA ND, PROIETTI R, RUSSO MG, CALABRÒ R, POLITANO L. The effect of atrial preference pacing on atrial fibrillation electrophysiological substrate in Myotonic Dystrophy type 1 population. Acta Myol 2014; 33: 127-135.
23. RUSSO V, DI MEO F, RAGO A, PAPA AA, MOLINO A, MOSELLA M, POLITANO L, RUSSO MG, NIGRO G. Paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: P wave duration and dispersion analysis. Eur Rev Med Pharmacol Sci 2015; 19: 1241-1248.
24. RUSSO V, RAGO A, PANNONE B, DI MEO F, PAPA AA, MAYER MC, SPASIANO A, RUSSO MG, GOLINO P, CALABRÒ R, NIGRO G. Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. Int J Hematol 2011; 93: 446-451.
25. RUSSO V, RAGO A, PANNONE B, PAPA AA, MAYER MC, SPASIANO A, CALABRÒ R, RUSSO MG, NIGRO G. Atrial fibrillation and beta thalassemia major: the predictive role of the 12-lead electrocardiogram analysis. Indian Pacing Electrophysiol J 2014; 14: 121-132.
26. RUSSO V, RAGO A, DI MEO F, PAPA AA, CIARDIELLO C, CRISTIANO A, CALABRÒ R, RUSSO MG, NIGRO G. Atrial septal aneurysm and supraventricular arrhythmias: the role of atrial electromechanical delay. Echocardiography 2015; 32: 1504-1514.
27. PROIETTI R, RUSSO V, SAGONE A, VIECCA M, SPODICK DH. Interatrial block: an under-recognized electrocardiographic diagnosis with important clinicaltherapeutic implications. G Ital Cardiol (Rome) 2014; 15: 561-568.
28. STABILE G, RUSSO V, RAPACCIUOLO A, DE DIVITIIS M, DE SIMONE A, SOLIMENE F, D'ONOFRIO A, IULIANO A, MARESCA G, ESPOSITO F, LA ROCCA V, SCHILLACI V, DE CRESCENZO I, LOSI MA, LIBRERA M. Transesophageal echocardiography in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry. Int J Cardiol 2015; 184: 283-284.
29. NAGARAKANTI R, EZEKOWITZ MD, OLDGREN J, YANG S, CHERNICK M, AIKENS TH, FLAKER G, BRUGADA J, KAMENSKY G, PAREKH A, REILLY PA, YUSUF S, CONNOLLY SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.